Terms: = Breast cancer AND MUC16, CA125, CA-125
543 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Potential Value of HSP90α in Prognosis of Triple-Negative breast cancer.
Wang HF; Chen Y; Cao B; Pei J
Med Sci Monit; 2024 Mar; 30():e943049. PubMed ID: 38553816
[TBL] [Abstract] [Full Text] [Related]
3. Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD.
Chen M; Zhang X; Ming Z; Lingyu ; Feng X; Han Z; An HX
J Transl Med; 2024 Mar; 22(1):315. PubMed ID: 38539235
[TBL] [Abstract] [Full Text] [Related]
4. BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian cancer Occurrence? A Multicenter Retrospective Study.
Loizzi V; Mongelli M; Arezzo F; Romagno I; Cazzato G; Popescu O; Legge F; Trerotoli P; Silvestris E; Kardhashi A; Cormio G
Gynecol Obstet Invest; 2024; 89(2):87-94. PubMed ID: 38246147
[TBL] [Abstract] [Full Text] [Related]
5. Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy.
Yin G; Liu L; Yu T; Yu L; Feng M; Zhou C; Wang X; Teng G; Ma Z; Zhou W; Ye C; Zhang J; Ji C; Zhao L; Zhou P; Guo Y; Meng X; Fu Q; Zhang Q; Li L; Zhou F; Zheng C; Xiang Y; Guo M; Wang Y; Wang F; Huang S; Yu Z
Genome Med; 2024 Jan; 16(1):11. PubMed ID: 38217005
[TBL] [Abstract] [Full Text] [Related]
6. Machine learning-based models for the prediction of breast cancer recurrence risk.
Zuo D; Yang L; Jin Y; Qi H; Liu Y; Ren L
BMC Med Inform Decis Mak; 2023 Nov; 23(1):276. PubMed ID: 38031071
[TBL] [Abstract] [Full Text] [Related]
7. Hepatitis C virus may accelerate breast cancer progression by increasing mutant p53 and c-Myc oncoproteins circulating levels.
Fathy A; Abdelrazek MA; Attallah AM; Abouzid A; El-Far M
Breast Cancer; 2024 Jan; 31(1):116-123. PubMed ID: 37973687
[TBL] [Abstract] [Full Text] [Related]
8. Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.
Chi Y; Su M; Zhou D; Zheng F; Zhang B; Qiang L; Ren G; Song L; Bu B; Fang S; Yu B; Zhou J; Yu J; Li H
Elife; 2023 Nov; 12():. PubMed ID: 37929934
[TBL] [Abstract] [Full Text] [Related]
9. Development and validation of prediction model for early warning of ovarian metastasis risk of endometrial carcinoma.
Zhao Q; Li Y; Wang T
Medicine (Baltimore); 2023 Oct; 102(41):e35439. PubMed ID: 37832099
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Efficacy of Neoadjuvant Chemotherapy plus Modified Radical Mastectomy for Stage II-III breast cancer Patients and Its Influence on Serum Tumor Markers.
Yan S; Li J; Chen J; Zhou Y; Qiu Y; Chen Y; Wu W
Altern Ther Health Med; 2024 Jan; 30(1):260-264. PubMed ID: 37773687
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation of Serum Fructosamine as Diagnostic Marker of Postoperative Recurrence in the Patients with breast cancer.
Zhao Y; Xie X; Xie J; Zhang L; Li B; Liu J; Jiang H
Biomed Res Int; 2023; 2023():6435776. PubMed ID: 37475819
[TBL] [Abstract] [Full Text] [Related]
12. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
13. ca125 Levels in BRCA mutation carriers - a retrospective single center cohort study.
Gebhart P; Singer CF; Gschwantler-Kaulich D
BMC Cancer; 2023 Jul; 23(1):610. PubMed ID: 37393265
[TBL] [Abstract] [Full Text] [Related]
14. Development and validation of a muc16 mutation-associated immune prognostic model for lung adenocarcinoma.
Liu H; Xin T; Duan H; Wang Y; Shao C; Zhu Y; Wang J; He J
Aging (Albany NY); 2023 Jun; 15(12):5650-5661. PubMed ID: 37341998
[TBL] [Abstract] [Full Text] [Related]
15. Development and validation of a nomogram to predict Chinese breast cancer risk based on clinical serum biomarkers.
Li N; Cao L; Zhao K; Feng Y
Biomark Med; 2023 Mar; 17(5):273-286. PubMed ID: 37284737
[No Abstract] [Full Text] [Related]
16. Randomized trial of exercise on cancer-related blood biomarkers and survival in women with ovarian cancer.
Cartmel B; Li FY; Zhou Y; Gottlieb L; Lu L; Mszar R; Harrigan M; Ligibel JA; Gogoi R; Schwartz PE; Risch HA; Irwin ML
Cancer Med; 2023 Jul; 12(14):15492-15503. PubMed ID: 37269192
[TBL] [Abstract] [Full Text] [Related]
17. MicroRNA Dysregulation in Early breast cancer Diagnosis: A Systematic Review and Meta-Analysis.
Garrido-Palacios A; Rojas Carvajal AM; Núñez-Negrillo AM; Cortés-Martín J; Sánchez-García JC; Aguilar-Cordero MJ
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175974
[TBL] [Abstract] [Full Text] [Related]
18. Could uterine conservation be an option in presumed early-stage epithelial ovarian cancer?
Benoit L; Pajot C; Koual M; Nguyen-Xuan HT; Bentivegna E; Bats AS; Azaïs H
Arch Gynecol Obstet; 2023 Sep; 308(3):953-960. PubMed ID: 37031304
[TBL] [Abstract] [Full Text] [Related]
19. Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews.
Voss T; Krag M; Martiny F; Heleno B; Jørgensen KJ; Brandt Brodersen J
Cancer Epidemiol; 2023 Jun; 84():102352. PubMed ID: 36963292
[TBL] [Abstract] [Full Text] [Related]
20. Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.
Gunnarsdottir FB; Bendahl PO; Johansson A; Benfeitas R; Rydén L; Bergenfelz C; Larsson AM
Breast Cancer Res; 2023 Mar; 25(1):29. PubMed ID: 36945037
[TBL] [Abstract] [Full Text] [Related]
[Next]
